C-Bridge Cap­i­tal closes sec­ond health­care fund at $400M

BioSpectrum (Asia) - - Finance News -

C-Bridge Cap­i­tal, a Chi­nese pri­vate equity firm tar­get­ing the health­care sec­tor, has closed its sec­ond fund, C-Bridge Health­care Fund II at its hard cap of $400 mil­lion. The lat­est fund as well as its first fund, which was closed at a $200 mil­lion cap in 2014, are fo­cus­ing on late stage com­pa­nies in the fields of biotech­nol­ogy, phar­ma­ceu­ti­cals, med­i­cal de­vices and health care.

The fund is keen on in­vest­ing in the treat­ment of Hep­ati­tis B and lung can­cer, due to the grow­ing num­ber of smok­ers and pol­lu­tion lev­els in China. Since the first quar­ter this year, C-Bridge has teamed up with Tian­jin-based Tasly Hold­ing Group to in­vest $150 mil­lion in drug de­vel­oper Tianzhen­shi Biotech­nol­ogy Com­pany.

It also led a $100-mil­lion fund­ing round in phar­ma­ceu­ti­cal startup As­cle­tis as well as in­vested $25 mil­lion in med­i­cal equip­ment pro­ducer An­rei Med­i­cal (Hangzhou) Co Ltd. C-Bridge Cap­i­tal has sep­a­rately set up I-Bridge Cap­i­tal, a $100-mil­lion ven­ture cap­i­tal fund, to in­vest in Chi­nese star­tups in phar­ma­ceu­ti­cal, biotech and health­care ser­vices.

In Au­gust last year, I-Bridge teamed up with Is­raeli bio­pharma firm BioLineRX Ltd to launch a new med­i­cal de­vel­oper in China. C-Bridge cur­rently has around $700 mil­lion in as­sets un­der man­age­ment. It has more than 20 team mem­bers at of­fices in Shang­hai, Beijing, Bos­ton and

San Diego.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.